A novel nest hybridization chain reaction based electrochemical assay for sensitive detection of circulating tumor DNA

2020 ◽  
Vol 1107 ◽  
pp. 40-47 ◽  
Author(s):  
YiFang Huang ◽  
MaLiang Tao ◽  
ShiHua Luo ◽  
Ye Zhang ◽  
Bo Situ ◽  
...  
Keyword(s):  
Circulating Tumor Dna ◽  
Sensitive Detection ◽  
Hybridization Chain Reaction ◽  
Chain Reaction ◽  
Electrochemical Assay ◽  
Tumor Dna

scholarly journals Ultra-sensitive detection of circulating tumor DNA identifies patients in high risk of recurrence in early stages melanoma

2019 ◽  
Vol 30 ◽  
pp. v767
Author(s):  
F. Janku ◽  
H.J. Huang ◽  
I. Treskova ◽  
K. Pivovarcikova ◽  
S.G. Call ◽  
...  
Keyword(s):  
High Risk ◽  
Circulating Tumor Dna ◽  
Sensitive Detection ◽  
Risk Of Recurrence ◽  
Early Stages ◽  
Tumor Dna

Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction

2020 ◽  
Vol 58 (4) ◽  
pp. 527-532 ◽  
Author(s):  
Jee-Soo Lee ◽  
Miyoung Kim ◽  
Moon-Woo Seong ◽  
Han-Sung Kim ◽  
Young Kyung Lee ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Circulating Tumor Dna ◽  
Analytical Sensitivity ◽  
Dna Fragments ◽  
Chain Reaction ◽  
Specimen Type ◽  
Dna Fragment ◽  
Polymerase Chain ◽  
Ctdna Analysis ◽  
Tumor Dna

AbstractBackgroundChoosing the specimen type is the first step of the pre-analytical process. Previous reports suggested plasma as the optimal specimen for circulating tumor DNA (ctDNA) analysis. However, head-to-head comparisons between plasma and serum using platforms with high analytical sensitivity, such as droplet digital polymerase chain reaction (ddPCR), are limited, and several recent studies have supported the clinical utility of serum-derived ctDNA. This study aimed to compare the DNA profiles isolated from plasma and serum, characterize the effects of the differences between specimens on ctDNA measurement, and determine the major contributors to these differences.MethodsWe isolated cell-free DNA (cfDNA) from 119 matched plasma/serum samples from cancer patients and analyzed the cfDNA profiles by DNA fragment sizing. We then assessed KRAS mutations in ctDNA from matched plasma/serum using ddPCR.ResultsThe amount of large DNA fragments was increased in serum, whereas that of cfDNA fragments (<800 bp) was similar in both specimens. ctDNA was less frequently detected in serum, and the KRAS-mutated fraction in serum was significantly lower than that in plasma. The differences in ctDNA fractions between the two specimen types correlated well with the amount of large DNA fragments and white blood cell and neutrophil counts.ConclusionsOur results provided detailed insights into the differences between plasma and serum using DNA fragment sizing and ddPCR, potentially contributing to ctDNA analysis standardization. Our study also suggested that using plasma minimizes the dilution of tumor-derived DNA and optimizes the sensitivity of ctDNA analysis. So, plasma should be the preferred specimen type.

Sign in / Sign up

Export Citation Format

Share Document